Prolyl isomerase Pin1 as a molecular target for cancer diagnostics and therapeutics

Cancer Cell

Volumn 4, Issue 3, 2003, Pages 175-180

  Lu, Kun Ping ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLOPHILIN; FK 506 BINDING PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; ISOMERASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOTRANSFERASE; PROLINE; PROLYL ISOMERASE; RAS PROTEIN; SERINE; THREONINE; UNCLASSIFIED DRUG;

CANCER DIAGNOSIS; CANCER THERAPY; CARCINOGENESIS; CATALYSIS; CATALYST; CELL PROLIFERATION; CELL TRANSFORMATION; ENZYME SPECIFICITY; ENZYME SUBSTRATE COMPLEX; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

EID: 0141457429     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(03)00218-6     Document Type: Review

References (35)

1. Ayala G., Wang D., Wulf G., Frolov A., Le R., Wheeler T., Sowadski J.M., Lu K.P., Bao L. Pin1 is a novel prognostic marker in prostate cancer. Cancer Res. in press:2003.
2. Blume-Jensen P., Hunter T. Oncogenic kinase signalling. Nature. 411:2001;355-365.
3. Chao S.H., Greenleaf A.L., Price D.H. Juglone, an inhibitor of the peptidyl-prolyl isomerase Pin1, also directly blocks transcription. Nucleic Acids Res. 29:2001;767-773.
4. Deininger M.W., O'Brien S.G., Ford J.M., Druker B.J. Practical management of patients with chronic myeloid leukemia receiving imatinib. J. Clin. Oncol. 21:2003;1637-1647.
5. Dhanasekaran S.M., Barrette T.R., Ghosh D., Shah R., Varambally S., Kurachi K., Pienta K.J., Rubin M.A., Chinnaiyan A.M. Delineation of prognostic biomarkers in prostate cancer. Nature. 412:2001;822-826.
6. Druker B.J. Perspectives on the development of a molecularly targeted agent. Cancer Cell. 1:2002;31-36.
7. Fujimori F., Takahashi K., Uchida C., Uchida T. Mice lacking Pin1 develop normally, but are defective in entering cell cycle from G(0) arrest. Biochem. Biophys. Res. Commun. 265:1999;658-663.
8. Harries M., Smith I. The development and clinical use of trastuzumab (Herceptin). Endocr. Relat. Cancer. 9:2002;75-85.
9. Hennig L., Christner C., Kipping M., Schelbert B., Rucknagel K.P., Grabley S., Kullertz G., Fischer G. Selective inactivation of parvulin-like peptidyl-prolyl cis/trans isomerases by juglone. Biochemistry. 37:1998;5953-5960.
10. Hunter T. Prolyl isomerase and nuclear function. Cell. 92:1998;141-143.
11. Lin S.Y., Xia W., Wang J.C., Kwong K.Y., Spohn B., Wen Y., Pestell R.G., Hung M.C. Beta-catenin, a novel prognostic marker for breast cancer. its roles in cyclin D1 expression and cancer progression Proc. Natl. Acad. Sci. USA. 97:2000;4262-4266.
12. Liou Y.C., Ryo R., Huang H.K., Lu P.J., Bronson R., Fujimori F., Uchida U., Hunter T., Lu K.P. Loss of Pin1 function in the mouse resembles the cyclin D1-null phenotypes. Proc. Natl. Acad. Sci. USA. 99:2002;1335-1340.
13. Liou Y.-C., Sun A., Ryo A., Zhou X.Z., Yu Z.-X., Huang H.-K., Bronson R., Bing G., Li X., Hunter T., Lu K.P. Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration. Nature. 424:2003;556-561.
14. Lu K.P., Hanes S.D., Hunter T. A human peptidyl-prolyl isomerase essential for regulation of mitosis. Nature. 380:1996;544-547.
15. Lu P.J., Wulf G., Zhou X.Z., Davies P., Lu K.P. The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature. 399:1999;784-788. a.
16. Lu P.J., Zhou X.Z., Shen M., Lu K.P. A function of WW domains as phosphoserine- or phosphothreonine-binding modules. Science. 283:1999;1325-1328. b.
17. Lu P.J., Zhou X.Z., Liou Y.C., Noel J.P., Lu K.P. Critical role of WW domain phosphorylation in regulating its phosphoserine-binding activity and the Pin1 function. J. Biol. Chem. 277:2002;2381-2384. a.
18. Lu K.P., Liou Y.C., Zhou X.Z. Pinning down the proline-directed phosphorylation signaling. Trends Cell Biol. 12:2002;164-172. b.
19. Nevins J.R. The Rb/E2F pathway and cancer. Hum. Mol. Genet. 10:2001;699-703.
20. Ranganathan R., Lu K.P., Hunter T., Noel J.P. Structural and functional analysis of the mitotic peptidyl-prolyl isomerase Pin1 suggests that substrate recognition is phosphorylation dependent. Cell. 89:1997;875-886.
21. Rippmann J.F., Hobbie S., Daiber C., Guilliard B., Bauer M., Birk J., Nar H., Garin-Chesa P., Rettig W.J., Schnapp A. Phosphorylation-dependent proline isomerization catalyzed by Pin1 is essential for tumor cell survival and entry into mitosis. Cell Growth Differ. 11:2000;409-416.
22. Ryo A., Nakamura N., Wulf G., Liou Y.C., Lu K.P. Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC. Nat. Cell Biol. 3:2001;793-801.
23. Ryo A., Liou Y.C., Wulf G., Nakamura N., Lee S.W., Lu K.P. Pin1 is an E2F target gene essential for the Neu/Ras-induced transformation of mammary epithelial cells. Mol. Cell. Biol. 22:2002;5281-5295.
24. Ryo A., Liou Y.C., Lu K.P., Wulf G. Prolyl isomerase Pin1, a catalyst for oncogenesis and a potential anticancer target. J. Cell Sci. 116:2003;773-783.
25. Shen M., Stukenberg P.T., Kirschner M.W., Lu K.P. The essential mitotic peptidyl-prolyl isomerase Pin1 binds and regulates mitosis-specific phosphoproteins. Genes Dev. 12:1998;706-720.
26. Singh D., Febbo P.G., Ross K., Jackson D.G., Manola J., Ladd C., Tamayo P., Renshaw A.A., D'Amico A.V., Richie J.P.et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell. 1:2002;203-209.
27. Uchida T., Takamiya M., Takahashi M., Miyashita H., Ikeda H., Terada T., Matsuo Y., Shirouzu M., Yokoyama S., Fujimori F., Hunter T. Pin1 and Par14 peptidyl prolyl isomerase inhibitors block cell proliferation. Chem. Biol. 10:2003;15-24.
28. Weiwad M., Kullertz G., Schutkowski M., Fischer G. Evidence that the substrate backbone conformation is critical to phosphorylation by p42 MAP kinase. FEBS Lett. 478:2000;39-42.
29. Wulf G.M., Ryo A., Wulf G.G., Lee S.W., Niu T., Lu K.P. Pin1 is overexpressed in breast cancer and potentiates the transcriptional activity of phosphorylated c-Jun towards the cyclin D1 gene. EMBO J. 20:2001;3459-3472.
30. Wulf G.M., Liou Y.C., Ryo A., Lee S.W., Lu K.P. Role of Pin1 in the regulation of p53 stability and p21 transactivation, and cell cycle checkpoints in response to DNA damage. J. Biol. Chem. 277:2002;47976-47979.
31. Yaffe M.B., Schutkowski M., Shen M., Zhou X.Z., Stukenberg P.T., Rahfeld J., Xu J., Kuang J., Kirschner M.W., Fischer G.et al. Sequence-specific and phosphorylation-dependent proline isomerization. A potential mitotic regulatory mechanism Science. 278:1997;1957-1960.
32. Yu Q., Geng Y., Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature. 411:2001;1017-1021.
33. Zacchi P., Gostissa M., Uchida T., Salvagno C., Avolio A., Voliniak S., Ronai Z., Blandino G., Schneider C., Del Sal G. The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. Nature. 419:2002;853-857.
34. Zheng H., You H., Zhou X.Z., Murray S.A., Uchida T., Wulf G., Gu L., Tang X., Lu K.P., Xiao Z.X.J. The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response. Nature. 419:2002;849-853.
35. Zhou X.Z., Kops O., Werner A., Lu P.J., Shen M., Stoller G., Küllertz G., Stark M., Fischer G., Lu K.P. Pin1-dependent prolyl isomerization regulates dephosphorylation of Cdc25C and tau proteins. Mol. Cell. 6:2000;873-883.